Just a few months after it shut a Santa Barbara facility, Botox-maker Allergan has re-entered the Tri-Counties, agreeing to buy Kythera Biopharmaceuticals Inc. for about $2.1 billion. The deal will add the Westlake Village-based Kythera’s treatments for double chins and male pattern baldness to Allergan’s existing line of products, including a breast implant operation formerly Read More →
On the back of its strong financial performance in 2014, Amgen, the Tri-Counties’ largest private employer, is set to begin shifting research operations away from its Thousand Oaks headquarters.
Sitting in public-company-listing limbo with a listing deadline on its current stock price, Thousand Oaks-based energy crop producer Ceres will attempt to continue its numerous pricey research projects by balancing them with new revenue streams.
Valedictorian will be an afterthought on resumes for Alexandra Kukoff, a half-deaf, 15-year-old Thousand Oaks-native who is attending high school and college simultaneously, working towards her associate’s degree in women’s history.
By Henry Dubroff / Friday, October 31st, 2014 / Latest news, Opinion, Top Stories / Comments Off on Dubroff: A tale of turnout, transition and the state of tri-county politics
Money and party lines still count. But in the end, turnout will matter most.
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”27-04-2014″ enddate=”27-10-2014″ width=”300″ height=”245″] Cost cutting moves and new drugs are starting to pay off for Amgen Inc., as the biotech giant raised earnings guidance after a stronger-than-expected third quarter. The company said Oct. 27 that strong demand for its white blood cell booster, Neulasta, and increased sales of newer Read More →
